{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:11Z","timestamp":1791287591276,"version":"4.1.0"},"reference-count":68,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["P50 DE026787"],"award-info":[{"award-number":["P50 DE026787"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002373"],"award-info":[{"award-number":["UL1 TR002373"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA262292"],"award-info":[{"award-number":["R01 CA262292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA131290"],"award-info":[{"award-number":["R01 CA131290"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37 CA255330"],"award-info":[{"award-number":["R37 CA255330"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022675","name":"Wisconsin Economic Development Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022675","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>AXL is a receptor tyrosine kinase implicated in epidermal growth factor receptor resistance. The primary objective of this study was to test the hypothesis, generated in preclinical studies, that low AXL correlates with clinical response to cetuximab in patients with head and neck cancer (HNC). The secondary objectives were to further describe the feasibility and safety of preoperative administration of cetuximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>We performed a single-site, single-arm, open-label, window-of-opportunity study utilizing preoperative cetuximab in 15 patients with HNC. Patients received two doses of cetuximab and underwent resection of their tumors. Biopsies were used to assess AXL expression and changes in Ki67 staining and to establish patient-derived xenografts (PDX). Single-cell RNA sequencing (scRNA-seq) of treated xenograft tissue was used to assess differences between sensitive and resistant tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifteen subjects were registered for treatment in the study, and fourteen completed treatment with cetuximab prior to surgical resection. No correlation between AXL expression at baseline and change in tumor size in response to cetuximab was observed. Preoperative cetuximab did not delay surgical resection, and no unexpected treatment-related adverse events were reported. scRNA-seq identified that cetuximab sensitivity is marked by transcriptional remodeling, whereas resistance is associated with stable human epidermal growth factor receptor signaling and elevated Tyro, AXL, and MerTK (TAM) activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Delivery of preoperative cetuximab is safe, and a short course can be utilized to identify patients with HNC responding to single-agent cetuximab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Preoperative cetuximab is safe and feasible in HNC, identifying early responders without delaying surgery. Although AXL was not validated as a resistance biomarker\u2014possibly due to COVID-19\u2013related early closure\u2014concordance among patient outcomes, circulating tumor cells, and PDXs strongly supports this translational pipeline for future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0258","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:05:12Z","timestamp":1788473112000},"page":"2325-2338","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5902-7430","authenticated-orcid":false,"given":"Justine Y.","family":"Bruce","sequence":"first","affiliation":[{"name":"1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-9381","authenticated-orcid":false,"given":"Tiffany A.","family":"Glazer","sequence":"additional","affiliation":[{"name":"3Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-2525","authenticated-orcid":false,"given":"Liliana L.","family":"Berube","sequence":"additional","affiliation":[{"name":"4Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-9610","authenticated-orcid":false,"given":"Colin A.","family":"Longhurst","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-3155","authenticated-orcid":false,"given":"Menggang","family":"Yu","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"5Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-9848","authenticated-orcid":false,"given":"Rong","family":"Hu","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"6Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5798-3341","authenticated-orcid":false,"given":"Aaron M.","family":"Wieland","sequence":"additional","affiliation":[{"name":"3Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-5505","authenticated-orcid":false,"given":"Paul M.","family":"Harari","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"4Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-7319","authenticated-orcid":false,"given":"Gregory K.","family":"Hartig","sequence":"additional","affiliation":[{"name":"3Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-8680","authenticated-orcid":false,"given":"Mari","family":"Iida","sequence":"additional","affiliation":[{"name":"4Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-1682","authenticated-orcid":false,"given":"Ranjit K.","family":"Mehta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00jmfr291","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Michigan 7 Department of Radiation Oncology, , Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-8821","authenticated-orcid":false,"given":"Theodore S.","family":"Lawrence","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00jmfr291","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Michigan 7 Department of Radiation Oncology, , Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-6962","authenticated-orcid":false,"given":"Mukesh K.","family":"Nyati","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00jmfr291","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Michigan 7 Department of Radiation Oncology, , Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0085-3957","authenticated-orcid":false,"given":"Michael J.","family":"Poellmann","sequence":"additional","affiliation":[{"name":"8Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-5109","authenticated-orcid":false,"given":"Jiyoon","family":"Bu","sequence":"additional","affiliation":[{"name":"8Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-128X","authenticated-orcid":false,"given":"Kwangok P.","family":"Nickel","sequence":"additional","affiliation":[{"name":"4Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9870-031X","authenticated-orcid":false,"given":"Seungpyo","family":"Hong","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"8Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, Madison, Wisconsin."},{"name":"9Lachman Institute for Pharmaceutical Development and Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-3675","authenticated-orcid":false,"given":"Deric L.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"4Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8336-8000","authenticated-orcid":false,"given":"Randall J.","family":"Kimple","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."},{"name":"4Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2026100607124064200_bib1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2026100607124064200_bib2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026100607124064200_bib3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"2026100607124064200_bib4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026100607124064200_bib5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.oraloncology.2014.12.011","article-title":"A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"51","author":"Gilbert","year":"2015","journal-title":"Oral Oncol"},{"key":"2026100607124064200_bib6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4161\/cbt.11.9.15050","article-title":"Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab","volume":"11","author":"Brand","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2026100607124064200_bib7","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res"},{"key":"2026100607124064200_bib8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/1078-0432.ccr-1100-03","article-title":"Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy","volume":"10","author":"Ciardiello","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib9","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-07-4905","article-title":"Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells","volume":"14","author":"Bianco","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib10","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members","volume":"27","author":"Wheeler","year":"2008","journal-title":"Oncogene"},{"key":"2026100607124064200_bib11","doi-asserted-by":"publisher","first-page":"e12702","DOI":"10.1371\/journal.pone.0012702","article-title":"Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma","volume":"5","author":"Hatakeyama","year":"2010","journal-title":"PLoS One"},{"key":"2026100607124064200_bib12","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/onc.2009.234","article-title":"Nuclear EGFR contributes to acquired resistance to cetuximab","volume":"28","author":"Li","year":"2009","journal-title":"Oncogene"},{"key":"2026100607124064200_bib13","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.1158\/0008-5472.CAN-07-0589","article-title":"Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab","volume":"67","author":"Lu","year":"2007","journal-title":"Cancer Res"},{"key":"2026100607124064200_bib14","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-11-0861","article-title":"Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer","volume":"17","author":"Argiris","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-07-2460","article-title":"Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells","volume":"68","author":"Fuchs","year":"2008","journal-title":"Cancer Res"},{"key":"2026100607124064200_bib16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2010.04.006","article-title":"Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells","volume":"296","author":"Kim","year":"2010","journal-title":"Cancer Lett"},{"key":"2026100607124064200_bib17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"2026100607124064200_bib18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"2026100607124064200_bib19","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-09-3145","article-title":"An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation","volume":"70","author":"Schoeberl","year":"2010","journal-title":"Cancer Res"},{"key":"2026100607124064200_bib20","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"Garrett","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026100607124064200_bib21","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1073\/pnas.1018001108","article-title":"Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors","volume":"109","author":"Chakrabarty","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026100607124064200_bib22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"key":"2026100607124064200_bib23","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"AXL mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res"},{"key":"2026100607124064200_bib24","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-14-2648","article-title":"AXL is a logical molecular target in head and neck squamous cell carcinoma","volume":"21","author":"Brand","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib25","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.ijrobp.2005.04.028","article-title":"Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade","volume":"62","author":"Li","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100607124064200_bib26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-9966-31-37","article-title":"Enhancement of radiation response with bevacizumab","volume":"31","author":"Hoang","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"2026100607124064200_bib27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/annonc\/mds245","article-title":"Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Argiris","year":"2013","journal-title":"Ann Oncol"},{"key":"2026100607124064200_bib28","doi-asserted-by":"publisher","first-page":"e2316094","DOI":"10.1001\/jamanetworkopen.2023.16094","article-title":"Long-term outcomes of bevacizumab and chemoradiation for locoregionally advanced nasopharyngeal carcinoma: a nonrandomized controlled trial","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026100607124064200_bib29","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1038\/ncomms13898","article-title":"Reprogramming the immunological microenvironment through radiation and targeting Axl","volume":"7","author":"Aguilera","year":"2016","journal-title":"Nat Commun"},{"key":"2026100607124064200_bib30","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","article-title":"Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer","volume":"23","author":"Skinner","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib31","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-19-3142","article-title":"AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer","volume":"26","author":"McDaniel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3892\/etm.2023.12147","article-title":"Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype","volume":"26","author":"Ji","year":"2023","journal-title":"Exp Ther Med"},{"key":"2026100607124064200_bib33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","article-title":"Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia","volume":"268","author":"Hong","year":"2008","journal-title":"Cancer Lett"},{"key":"2026100607124064200_bib34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/cas.12171","article-title":"Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes","volume":"104","author":"Kurokawa","year":"2013","journal-title":"Cancer Sci"},{"key":"2026100607124064200_bib35","doi-asserted-by":"publisher","first-page":"41064","DOI":"10.18632\/oncotarget.17026","article-title":"Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"2026100607124064200_bib36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells","volume":"2","author":"Dufies","year":"2011","journal-title":"Oncotarget"},{"key":"2026100607124064200_bib37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"2026100607124064200_bib38","doi-asserted-by":"publisher","first-page":"ra66","DOI":"10.1126\/scisignal.2004155","article-title":"The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells","volume":"6","author":"Meyer","year":"2013","journal-title":"Sci Signal"},{"key":"2026100607124064200_bib39","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"2026100607124064200_bib40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1541-7786.MCR-16-0157","article-title":"AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers","volume":"15","author":"Balaji","year":"2017","journal-title":"Mol Cancer Res"},{"key":"2026100607124064200_bib41","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3324\/haematol.2021.278369","article-title":"AXL\/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia","volume":"107","author":"Post","year":"2022","journal-title":"Haematologica"},{"key":"2026100607124064200_bib42","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.phrs.2023.106668","article-title":"Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis","volume":"188","author":"Lei","year":"2023","journal-title":"Pharmacol Res"},{"key":"2026100607124064200_bib43","doi-asserted-by":"publisher","first-page":"122230","DOI":"10.1016\/j.lfs.2023.122230","article-title":"Targeting GAS6\/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer","volume":"335","author":"Kim","year":"2023","journal-title":"Life Sci"},{"key":"2026100607124064200_bib44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/1078-0432.CCR-23-0163","article-title":"Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable","volume":"30","author":"Codilupi","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib45","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1038\/s41388-023-02810-7","article-title":"AXL activates YAP through the EGFR-LATS1\/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma","volume":"42","author":"Okamoto","year":"2023","journal-title":"Oncogene"},{"key":"2026100607124064200_bib46","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/0008-5472.CAN-23-1459","article-title":"AXL\/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer","volume":"84","author":"Marquez-Palencia","year":"2024","journal-title":"Cancer Res"},{"key":"2026100607124064200_bib47","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1002\/hed.26085","article-title":"Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin","volume":"42","author":"Swiecicki","year":"2020","journal-title":"Head Neck"},{"key":"2026100607124064200_bib48","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1158\/1078-0432.CCR-17-3078","article-title":"Multivalent binding and biomimetic cell rolling improves the sensitivity and specificity of circulating tumor cell capture","volume":"24","author":"Myung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib49","doi-asserted-by":"publisher","first-page":"216187","DOI":"10.1016\/j.canlet.2023.216187","article-title":"Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment","volume":"562","author":"Poellmann","year":"2023","journal-title":"Cancer Lett"},{"key":"2026100607124064200_bib50","doi-asserted-by":"publisher","first-page":"115117","DOI":"10.1016\/j.bios.2023.115117","article-title":"Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients","volume":"226","author":"Poellmann","year":"2023","journal-title":"Biosens Bioelectron"},{"key":"2026100607124064200_bib51","doi-asserted-by":"publisher","first-page":"e2300303","DOI":"10.1200\/PO.23.00303","article-title":"Prospective characterization of circulating tumor cell kinetics in patients with oligometastatic disease receiving definitive intent radiation therapy","volume":"7","author":"Sud","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2026100607124064200_bib52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026100607124064200_bib53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1078-0432.CCR-12-2746","article-title":"Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts","volume":"19","author":"Kimple","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib54","doi-asserted-by":"publisher","first-page":"e100995","DOI":"10.1371\/journal.pone.0100995","article-title":"Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts","volume":"9","author":"Stein","year":"2014","journal-title":"PLoS One"},{"key":"2026100607124064200_bib55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12967-021-02850-1","article-title":"Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients","volume":"19","author":"Abel","year":"2021","journal-title":"J Transl Med"},{"key":"2026100607124064200_bib56","doi-asserted-by":"crossref","DOI":"10.17504\/protocols.io.bp2l62bjkgqe\/v1","article-title":"Tumor dissociation to single cell suspension v1","author":"Berube","year":"2024"},{"key":"2026100607124064200_bib57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2026100607124064200_bib58","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"key":"2026100607124064200_bib59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"2026100607124064200_bib60","volume-title":"R: a language and environment for statistical computing [Internet]","author":"R Core Team","year":"2024"},{"key":"2026100607124064200_bib61","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1093\/annonc\/mdt180","article-title":"Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck","volume":"24","author":"Schmitz","year":"2013","journal-title":"Ann Oncol"},{"key":"2026100607124064200_bib62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1535-7163.MCT-17-0115","article-title":"Cotargeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC","volume":"16","author":"Swick","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026100607124064200_bib63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12885-022-09511-6","article-title":"AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer","volume":"22","author":"Iida","year":"2022","journal-title":"BMC Cancer"},{"key":"2026100607124064200_bib64","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.xcrm.2024.101703","article-title":"A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib","volume":"5","author":"Simoni-Nieves","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026100607124064200_bib65","doi-asserted-by":"publisher","first-page":"e05785","DOI":"10.1002\/advs.202505785","article-title":"EGFR: new insights on its activation and mutation in tumor and tumor immunotherapy","volume":"12","author":"Gu","year":"2025","journal-title":"Adv Sci"},{"key":"2026100607124064200_bib66","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/1078-0432.CCR-25-2201","article-title":"Long-term survival and molecular biomarker evaluation of a phase II cetuximab and nivolumab clinical trial in recurrent\/metastatic head and neck cancer","volume":"32","author":"Chaudhary","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026100607124064200_bib67","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/2767-9764.CRC-22-0443","article-title":"EGFR inhibition by cetuximab modulates hypoxia and IFN response genes in head and neck squamous cell carcinoma","volume":"3","author":"Chaudhary","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026100607124064200_bib68","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/cancers13051180","article-title":"Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results of phase I\/II study","volume":"13","author":"Chung","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0258\/3827195\/crc-26-0258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2325\/3835996\/crc-26-0258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2325\/3835996\/crc-26-0258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:12:53Z","timestamp":1791285173000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2325\/788730\/Window-of-Opportunity-Study-Utilizing-Preoperative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0258","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34086742","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086733","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086736","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086715","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086739","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34086730","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8756260","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}